We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.045 | -2.95% | 1.48 | 1.45 | 1.50 | 1.525 | 1.475 | 1.53 | 4,058,690 | 16:35:28 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.28 | 11.4M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/6/2021 16:49 | PATT forecast. We will drift to marginally below 50p. Then the RNS will come stating US up and selling. Then forget 50p in a good way. Key point. Do not resent a price drift and dip. Celebrate it and get extra value. I am buying Monday. Will let you know how many and what price as it happens...how exciting. If you are really bored I can give you an Umbria update. | purchaseatthetop | |
18/6/2021 10:49 | Going nowhere. Top slice news and letting the rest run.Or is no one else thinking Dividend payments in the future. | oapknob1 | |
18/6/2021 08:52 | No top ups today so far. No reports from Umbria. I am doing the worst job here which is termite protecting the beams. However, I am enjoying chevking ITX and seeing the share price rising. Seriously, diversity is fine and good. If you do not want to read it filter it. Simples. | purchaseatthetop | |
18/6/2021 08:23 | Are they still on track to launch by the end of June or not? That's all. I hope they are. I just don't like the lazy cut and paste RNS which omits the opportunity to restate their position of being on track to launch by end of June 2021. Why not cut and paste that from the 21st May RNS ? I hope they are on track and look forward to future dividends here. | oapknob1 | |
18/6/2021 08:18 | Trev, its the same wording in a number of previous RNS's in the about Shield section,...GL S | swizz | |
18/6/2021 08:10 | I can't read any RNS stating a delay. The end of all the RNS read the same. | little minx | |
18/6/2021 08:08 | Which bit are you referring to that sounds like a delay? Literally just a directorate change with no detail regarding US launch | eastlands | |
18/6/2021 08:06 | Agree reads as delay omitting "June" from wording. Now with new CEO in place and other recent hires, it could be a long term positive ie he didn't like their current proposed marketing strategy and is already changing things around. However, short term it is undoubtedly a negative as any delay is. | reviewwworld | |
18/6/2021 07:52 | It's the same on all of them | little minx | |
18/6/2021 07:49 | 18/6/21 - The Group plans to launch Accrufer(R) in the US during 2021 through a highly experienced sales and marketing team. London, UK, 21 May 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru(R)/Accrufer | oapknob1 | |
18/6/2021 07:44 | Not happy with the wording in this RNS. Sounds like a delay | oapknob1 | |
17/6/2021 18:03 | My pain is far greater than six days. Will continue to hold as i see great potential but do not worry there will not be any more rhetorical questions from me. | friskymickey | |
17/6/2021 16:43 | Lol , wish I never got involved ! | cafc69 | |
17/6/2021 16:17 | Strange trading sessions recently | eastlands | |
17/6/2021 14:56 | That is during the six days you have been a member of advfn... ? (Rhetorical question, isn't it?) | livewireplus | |
17/6/2021 14:11 | Great fun watching this go down every day :( | friskymickey | |
17/6/2021 14:11 | Great fun watching this go down every day :( | friskymickey |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions